Régression clinique et capillaroscopique après autogreffe de moelle d’une sclérodermie systémique cutanée limitée associée à un lymphome anaplasique CD30

Bellis, R.; Françès, Camille; Barète, Stéphane; Senet, Patricia

doi:10.1016/j.annder.2014.04.116

Cited by 5 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a case report, Bellis et al [ 52 ] described a patient with cutaneous limited SSc who was diagnosed with CD30 positive anaplastic lymphoma. The patient received a bone marrow transplantation which resulted in a complete remission of the lymphoma, as well as the disappearance of the sclerodactyly and other signs of SSc.…”

Section: Association Of Ssc With Malignancymentioning

confidence: 99%

Systemic Sclerosis and Malignancy: A Review of Current Data

2016

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is associated with increased risk of malignancy. The organ systems most commonly affected are the lungs, the breasts and the hematological system. Risk factors predisposing a SSc patient for development of malignancy are not well defined, and the pathogenic basis of the association is yet to be explained. The incidence of malignancies in SSc patients is variable from one report to another, but most importantly, questions regarding the role of immunosuppressive therapies and the effect of autoantibodies have weak or sometimes contradictory answers in most of the currently available literature and physicians have no available guidelines to screen their SSc patients for malignancies. The lack of a concretely defined high-risk profile and the absence of malignancy screening guidelines tailored for SSc patients raise the importance of the need for more studies on the association of SSc and cancer and should incite rheumatology colleges to develop specific recommendations for the clinician to follow while approaching patients with SSc.

show abstract

Section: Association Of Ssc With Malignancymentioning

confidence: 99%

Systemic Sclerosis and Malignancy: A Review of Current Data

2016

View full text Add to dashboard Cite

show abstract

“…La survenue d'un cancer est plus fréquente chez les patients ayant des anticorps anti-RNA polymérase III avec un risque multiplié par 6 [30]. La régression de la symptomatologie après traitement de la tumeur sous-jacente a été rapportée dans quelques cas [31].…”

Section: Sclérodermie Paranéoplasiqueunclassified

Les syndromes paranéoplasiques en rhumatologie

et al. 2016

View full text Add to dashboard Cite

Les syndromes paranéoplasiques sont un groupe d’affections associées à des tumeurs malignes indépendamment reliés à leurs sièges ou à leurs tailles. L’étiopathogénie incrimine des mécanismes immunitaires humoraux ou cellulaires à l’encontre des cellules tumorales. Les syndromes paranéoplasiques en rhumatologie sont rares, intéressant essentiellement les articulations, les muscles, les os, les fascias ou les vaisseaux. L’apparition de signes rhumatologiques peut précéder ou faire suite au diagnostic d’un cancer, L’intervalle entre les deux souvent ne dépasse pas plus de 3 ans, leur connaissance permet d’orienter la prise en charge de ces malades qui doit être essentiellement carcinologique.

show abstract

“…In patients with MF, transformation to large cell histology is associated with worse prognosis. Paraneoplastic scleroderma has been reported arising within the context of lung, breast, and hematologic malignancies, 1 but its association with T-cell lymphomas is exceedingly rare 2, 3, 4, 5. We present the case of a woman with MF with CD30 + large cell transformation who also had the progressive sclerodermoid skin changes of paraneoplastic scleroderma.…”

Section: Introductionmentioning

confidence: 99%